Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection

Julia C. Gage, Hormuzd A. Katki, Mark Schiffman, Barbara Fetterman, Nancy E. Poitras, Thomas Lorey, Li C. Cheung, Philip E. Castle, Walter K. Kinney

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

It is unclear whether a woman's age influences her risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) upon detection of HPV. A large change in risk as women age would influence vaccination and screening policies. Among 972,029 women age 30-64 undergoing screening with Pap and HPV testing (Hybrid Capture 2, Qiagen, Germantown, MD) at Kaiser Permanente Northern California (KPNC), we calculated age-specific 5-year CIN3+ risks among women with HPV infections detected at enrollment, and among women with "newly detected" HPV infections at their second screening visit. Women (57,899, 6.0%) had an enrollment HPV infection. Among the women testing HPV negative at enrollment with a second screening visit, 16,724 (3.3%) had a newly detected HPV infection at their second visit. Both enrollment and newly detected HPV rates declined with age (p < 0.001). Women with enrollment versus newly detected HPV infection had higher 5-year CIN3+ risks: 8.5% versus 3.9%, (p < 0.0001). Risks did not increase with age but declined slightly from 30-34 years to 60-64 years: 9.4% versus 7.4% (p = 0.017) for enrollment HPV and 5.1% versus 3.5% (p = 0.014) for newly detected HPV. Among women age 30-64 in an established screening program, women with newly detected HPV infections were at lower risk than women with enrollment infections, suggesting reduced benefit vaccinating women at older ages. Although the rates of HPV infection declined dramatically with age, the subsequent CIN3+ risks associated with HPV infection declined only slightly. The CIN3+ risks among older women are sufficiently elevated to warrant continued screening through age 65.

Original languageEnglish (US)
Pages (from-to)1665-1671
Number of pages7
JournalInternational Journal of Cancer
Volume136
Issue number7
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Infection
Cervical Intraepithelial Neoplasia
Vaccination

Keywords

  • Age
  • Cancer prevention
  • Cervical intraepithelial neoplasia
  • Cytology
  • Human Papillomavirus
  • Hybrid capture 2

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Gage, J. C., Katki, H. A., Schiffman, M., Fetterman, B., Poitras, N. E., Lorey, T., ... Kinney, W. K. (2015). Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection. International Journal of Cancer, 136(7), 1665-1671. https://doi.org/10.1002/ijc.29143

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection. / Gage, Julia C.; Katki, Hormuzd A.; Schiffman, Mark; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Castle, Philip E.; Kinney, Walter K.

In: International Journal of Cancer, Vol. 136, No. 7, 01.04.2015, p. 1665-1671.

Research output: Contribution to journalArticle

Gage, JC, Katki, HA, Schiffman, M, Fetterman, B, Poitras, NE, Lorey, T, Cheung, LC, Castle, PE & Kinney, WK 2015, 'Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection', International Journal of Cancer, vol. 136, no. 7, pp. 1665-1671. https://doi.org/10.1002/ijc.29143
Gage, Julia C. ; Katki, Hormuzd A. ; Schiffman, Mark ; Fetterman, Barbara ; Poitras, Nancy E. ; Lorey, Thomas ; Cheung, Li C. ; Castle, Philip E. ; Kinney, Walter K. / Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection. In: International Journal of Cancer. 2015 ; Vol. 136, No. 7. pp. 1665-1671.
@article{3a986408db454a1fa983dee6f29ebbd2,
title = "Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection",
abstract = "It is unclear whether a woman's age influences her risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) upon detection of HPV. A large change in risk as women age would influence vaccination and screening policies. Among 972,029 women age 30-64 undergoing screening with Pap and HPV testing (Hybrid Capture 2, Qiagen, Germantown, MD) at Kaiser Permanente Northern California (KPNC), we calculated age-specific 5-year CIN3+ risks among women with HPV infections detected at enrollment, and among women with {"}newly detected{"} HPV infections at their second screening visit. Women (57,899, 6.0{\%}) had an enrollment HPV infection. Among the women testing HPV negative at enrollment with a second screening visit, 16,724 (3.3{\%}) had a newly detected HPV infection at their second visit. Both enrollment and newly detected HPV rates declined with age (p < 0.001). Women with enrollment versus newly detected HPV infection had higher 5-year CIN3+ risks: 8.5{\%} versus 3.9{\%}, (p < 0.0001). Risks did not increase with age but declined slightly from 30-34 years to 60-64 years: 9.4{\%} versus 7.4{\%} (p = 0.017) for enrollment HPV and 5.1{\%} versus 3.5{\%} (p = 0.014) for newly detected HPV. Among women age 30-64 in an established screening program, women with newly detected HPV infections were at lower risk than women with enrollment infections, suggesting reduced benefit vaccinating women at older ages. Although the rates of HPV infection declined dramatically with age, the subsequent CIN3+ risks associated with HPV infection declined only slightly. The CIN3+ risks among older women are sufficiently elevated to warrant continued screening through age 65.",
keywords = "Age, Cancer prevention, Cervical intraepithelial neoplasia, Cytology, Human Papillomavirus, Hybrid capture 2",
author = "Gage, {Julia C.} and Katki, {Hormuzd A.} and Mark Schiffman and Barbara Fetterman and Poitras, {Nancy E.} and Thomas Lorey and Cheung, {Li C.} and Castle, {Philip E.} and Kinney, {Walter K.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/ijc.29143",
language = "English (US)",
volume = "136",
pages = "1665--1671",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection

AU - Gage, Julia C.

AU - Katki, Hormuzd A.

AU - Schiffman, Mark

AU - Fetterman, Barbara

AU - Poitras, Nancy E.

AU - Lorey, Thomas

AU - Cheung, Li C.

AU - Castle, Philip E.

AU - Kinney, Walter K.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - It is unclear whether a woman's age influences her risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) upon detection of HPV. A large change in risk as women age would influence vaccination and screening policies. Among 972,029 women age 30-64 undergoing screening with Pap and HPV testing (Hybrid Capture 2, Qiagen, Germantown, MD) at Kaiser Permanente Northern California (KPNC), we calculated age-specific 5-year CIN3+ risks among women with HPV infections detected at enrollment, and among women with "newly detected" HPV infections at their second screening visit. Women (57,899, 6.0%) had an enrollment HPV infection. Among the women testing HPV negative at enrollment with a second screening visit, 16,724 (3.3%) had a newly detected HPV infection at their second visit. Both enrollment and newly detected HPV rates declined with age (p < 0.001). Women with enrollment versus newly detected HPV infection had higher 5-year CIN3+ risks: 8.5% versus 3.9%, (p < 0.0001). Risks did not increase with age but declined slightly from 30-34 years to 60-64 years: 9.4% versus 7.4% (p = 0.017) for enrollment HPV and 5.1% versus 3.5% (p = 0.014) for newly detected HPV. Among women age 30-64 in an established screening program, women with newly detected HPV infections were at lower risk than women with enrollment infections, suggesting reduced benefit vaccinating women at older ages. Although the rates of HPV infection declined dramatically with age, the subsequent CIN3+ risks associated with HPV infection declined only slightly. The CIN3+ risks among older women are sufficiently elevated to warrant continued screening through age 65.

AB - It is unclear whether a woman's age influences her risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) upon detection of HPV. A large change in risk as women age would influence vaccination and screening policies. Among 972,029 women age 30-64 undergoing screening with Pap and HPV testing (Hybrid Capture 2, Qiagen, Germantown, MD) at Kaiser Permanente Northern California (KPNC), we calculated age-specific 5-year CIN3+ risks among women with HPV infections detected at enrollment, and among women with "newly detected" HPV infections at their second screening visit. Women (57,899, 6.0%) had an enrollment HPV infection. Among the women testing HPV negative at enrollment with a second screening visit, 16,724 (3.3%) had a newly detected HPV infection at their second visit. Both enrollment and newly detected HPV rates declined with age (p < 0.001). Women with enrollment versus newly detected HPV infection had higher 5-year CIN3+ risks: 8.5% versus 3.9%, (p < 0.0001). Risks did not increase with age but declined slightly from 30-34 years to 60-64 years: 9.4% versus 7.4% (p = 0.017) for enrollment HPV and 5.1% versus 3.5% (p = 0.014) for newly detected HPV. Among women age 30-64 in an established screening program, women with newly detected HPV infections were at lower risk than women with enrollment infections, suggesting reduced benefit vaccinating women at older ages. Although the rates of HPV infection declined dramatically with age, the subsequent CIN3+ risks associated with HPV infection declined only slightly. The CIN3+ risks among older women are sufficiently elevated to warrant continued screening through age 65.

KW - Age

KW - Cancer prevention

KW - Cervical intraepithelial neoplasia

KW - Cytology

KW - Human Papillomavirus

KW - Hybrid capture 2

UR - http://www.scopus.com/inward/record.url?scp=84920939674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920939674&partnerID=8YFLogxK

U2 - 10.1002/ijc.29143

DO - 10.1002/ijc.29143

M3 - Article

VL - 136

SP - 1665

EP - 1671

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -